Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.

Genes & development - 15 Aug 2011

Garcia Daniel, Warr Matthew R, Martins Carla P, Brown Swigart Lamorna, Passegué Emmanuelle, Evan Gerard I

Abstract excerpt

MdmX, also known as Mdm4, is a critical negative regulator of p53, and its overexpression serves to block p53 tumor suppressor function in many cancers. Consequently, inhibiting MdmX has emerged as an attractive approach to restoring p53 function in those cancers that retain functional p53. Howev...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Apoptosis Regulatory Proteins
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Lymphoma

Share to Proto-Oncogene Proteins c-mdm2

Share to Proto-Oncogene Proteins c-myc

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 21852537
DOI: 10.1101/gad.16722111
PMCID: PMC3165938

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21852537-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.PMID 21852537Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?Semantic proximity Read ↗

Targeting Mdmx to treat breast cancers with wild-type p53.Semantic proximity Read ↗

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.Semantic proximity Read ↗

A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.Semantic proximity Read ↗

Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.Semantic proximity Read ↗

Pharmacological reactivation of p53 as a strategy to treat cancer.Semantic proximity Read ↗

Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX InteractionSemantic proximity Read ↗

Modeling the therapeutic efficacy of p53 restoration in tumors.Semantic proximity Read ↗

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.Semantic proximity Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.